A mechanistic pharmacokinetic–patient-derived organoid (PK–PDO) framework for comparing oxaliplatin HIPEC regimens in peritoneal metastases of colorectal cancer
Pouya Namakshenas, Roxan F.C.P.A. Helderman, Wim Ceelen, H. Petra Kok, Johannes Crezee. A mechanistic pharmacokinetic–patient-derived organoid (PK–PDO) framework for comparing oxaliplatin HIPEC regimens in peritoneal metastases of colorectal cancer. // European Journal of Pharmaceutical Sciences. – 2027. – DOI: 10.1016/j.ejps.2026.107702. – URL: https://doi.org/10.1016/j.ejps.2026.107702
Pouya Namakshenas, Roxan F.C.P.A. Helderman, Wim Ceelen, H. Petra Kok, & Johannes Crezee (2027). A mechanistic pharmacokinetic–patient-derived organoid (PK–PDO) framework for comparing oxaliplatin HIPEC regimens in peritoneal metastases of colorectal cancer. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2026.107702
Pouya Namakshenas, et al. “A mechanistic pharmacokinetic–patient-derived organoid (PK–PDO) framework for comparing oxaliplatin HIPEC regimens in peritoneal metastases of colorectal cancer.” European Journal of Pharmaceutical Sciences, 2027. doi:10.1016/j.ejps.2026.107702.
@article{Namakshenas2027,
title = {A mechanistic pharmacokinetic–patient-derived organoid (PK–PDO) framework for comparing oxaliplatin HIPEC regimens in peritoneal metastases of colorectal cancer},
author = {Namakshenas, Pouya and Helderman, Roxan F.C.P.A. and Ceelen, Wim and Kok, H. Petra and Crezee, Johannes},
journal = {European Journal of Pharmaceutical Sciences},
year = {2027},
doi = {10.1016/j.ejps.2026.107702},
url = {https://doi.org/10.1016/j.ejps.2026.107702}
}